Researchers at Stanford Medicine have engineered a two-part compound that transforms a primary driver of B-cell lymphoma into a mechanism for killing cancer cells. In mouse trials, administering the experimental drug twice daily led to the complete disappearance of aggressive lymphoma tumors within 11 days.
The study, published in Cell, represents a significant evolution in oncology strategy. Rather than merely inhibiting a cancer-promoting protein, the scientists designed a small molecule that physically links that protein to another capable of activating the cell’s innate programmed death pathways.
“We’re trying to essentially fight cancer with its cause — taking the driving force of the cancer and then rewiring it to activate cell death mechanisms,” said Gerald Crabtree, MD, the David Korn, MD, Professor in Pathology and a professor of developmental biology. Crabtree served as senior author alongside Nathanael Gray, PhD, Stephen Hinshaw, PhD, and Michael Green, PhD from MD Anderson Cancer Center. Lead authors include graduate student Meredith Nix and postdoctoral scholar Sai Gourisankar, PhD.
The research targets diffuse large B-cell lymphoma, the most prevalent form of non-Hodgkin lymphoma. The disease is frequently driven by BCL6, a protein that normally helps immune cells multiply by temporarily suppressing genes responsible for cell growth arrest and apoptosis. Under healthy conditions, BCL6 is deactivated once the immune threat subsides, allowing excess cells to die off. However, in lymphoma, BCL6 remains permanently active, continuously blocking these death signals and permitting malignant cells to proliferate unchecked.
To counter this, the team employed chemically induced proximity to create TCIP3. Nix described the compound as functioning like a two-sided key: one end binds to BCL6, while the other recruits proteins known as P300 and CBP. These recruited proteins add acetyl marks to BCL6, stripping it of its ability to silence downstream cell-death genes. Simultaneously, the acetylation loosens the DNA packaging structure, exposing genes to transcription factors that actively promote cell death.
“We’re not just relieving the repression conferred by BCL6; we’re also actively driving the expression of these cell death genes, which is why we’re able to get really potent compounds,” Nix explained, likening the approach to flooring the accelerator rather than simply releasing the brake.
Structural analysis revealed that TCIP3 acts as a “molecular glue,” forming additional chemical contacts that stabilize the protein complex more effectively than initially predicted. Using these insights, the researchers rigidified the connection between the molecule’s two halves, enhancing its potency and allowing it to kill lymphoma cells in laboratory settings at very low concentrations.
In vivo testing involved mice implanted with human lymphoma cells. By day 11, tumors in the treated group had vanished completely, while those in the control group persisted. The treatment showed no signs of toxicity or increased inflammatory signals, although it did eliminate germinal centers—clusters of rapidly dividing immune cells that rely on BCL6.
This elimination of germinal centers suggests potential therapeutic applications beyond cancer, particularly for autoimmune conditions such as rheumatoid arthritis and myasthenia gravis, where similar cell clusters play a pathological role.
While TCIP3 is not yet ready for human use and requires further refinement and testing across additional animal models, the underlying strategy holds broad promise. The team is now investigating other cancer-promoting proteins that might be susceptible to this type of molecular reprogramming.
The study involved contributions from MD Anderson Cancer Center and the AI-powered drug discovery platform Deep Origin. Funding was provided by the National Institutes of Health, the Howard Hughes Medical Institute, and several private foundations. Crabtree and Gray are founders and advisors for Shenandoah Therapeutics, which holds a license from Stanford for the TCIP technology.
Mouse models are promising but human biology is far more complex. I’ll be skeptical until clinical trials begin.
Finally, a direct approach against aggressive lymphoma without the brutal toxicity of traditional chemotherapy.
Molecular glue is becoming the new frontier in drug discovery. This is exactly the kind of innovation we need.
Does eliminating germinal centers permanently damage the immune system? That seems like a concerning long-term side effect.
Eleven days to complete tumor elimination? That speed is genuinely impressive compared to current treatments.
Groundbreaking work. Turning the enemy into an ally by reprogramming BCL6 is a brilliant oncology strategy.